Clinical Impact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

In this comprehensive online program for pathologists and medical oncologists gain expert guidance on optimal biomarker testing to identify patients with RET-dependent NSCLC and thyroid cancers and on integration of RET inhibitors into clinical practice. Read expert-authored commentaries listen to a podcast or watch an on-demand Webcast archived from a CCO live Webinar followed by downloading the associated slideset.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly